Device Trial Radar · NCT05609656
Electroporation and Immunotherapy in Metastatic Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Jun 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
4
Actual
Start
Jan 26, 2023
Primary completion
Apr 8, 2024
Study completion May 2, 2024
Sponsor
- Lead sponsor
- Ismail GögenurAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The trial is designed as an investigator initiated prospective phase 2 study in patients with metastatic pMMR colorectal cancer (CRC) to determine the safety and efficacy of calcium electroporation (CaEP) performed concurrently with irreversible electroporation (IRE) followed by a PD-1 inhibitor (pembrolizumab).
Conditions
- Metastatic Colorectal Cancer
Interventions
Irreversible electroporationDevice
Percutaneous ablation of a metastatic lesion. Irreversible electroporation is delivered through the NanoKnife system (AngioDynamics, New York, USA). The system is CE approved for medical use.
Calcium electroporationDevice
Just before the reversible electroporation, calcium chloride will be injected into the primary tumor. The electroporation will be delivered as at least four pulses and up to eight pulses. The device is repositioned after each pulse to ensure coverage of the entire surface area of the tumor. The reversible electroporation regime will be delivered through the endoscopic device EndoVE®, while the ePORE® will be used for pulse generation, both CE approved.
PembrolizumabDrug
Pembrolizumab 200 mg as an IV infusion every 3 weeks (+/- 3 days) for up to 12 months Pembrolizumab is an immune checkpoint inhibitor (PD-1-inhibitor).
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence rate of adverse events according to CTCAE v. 4.0Time frame: up to 1 month after end of treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zealand University Hospital
Køge, Denmark
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.